Trials / Completed
CompletedNCT02173574
Two-way Interaction Between Alisporivir and EDP239
An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients. The purpose of Part 2 is to inform the drug-drug interaction potential of EDP239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in Part 1, if observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DEB025 | |
| DRUG | EDP239 |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-06-25
- Last updated
- 2015-01-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02173574. Inclusion in this directory is not an endorsement.